Silver Lake and GIC have acquired "substantial" equity stakes in Ancestry.com. The deals, which value the provider of online family history data at $2.6 billion, were secured in part on belief in the potential of Ancestry to grow its DNA testing business.
More than a year after Cerus gained FDA approval--now the American Red Cross has bought into its technology with a multi-year deal for its Intercept Blood System for pathogen reduction in platelets and plasma. It's responsible for about 40% of the U.S. blood products, delivering 1.1 million plasma and 780,000 platelet units last year to almost 2,600 hospitals and transfusion centers.
Diagnostics giant Qiagen has joined the syndicate of Exosome Diagnostics--helping to distinguish this liquid biopsy startup from its growing crowd of peers. The pair are already partnered under a 2014 lung cancer diagnostic development deal. The Cambridge, MA-based startup has raised a $60 million Series B round to launch its liquid biopsy test via its CLIA-certified lab as well as to seek out companion diagnostics deals with biopharmas.
DNA and RNA hold a supercomputer's worth of information in a very small space in the nucleus of a cell. And how they are packed so tightly in such a tight volume can offer new ways to pack the material in synthetic capsules for the delivery of genetics-based therapeutics, researchers at North Carolina State University have said.
Researchers have developed a new technique that could enable an earlier and more accurate identification of the presence of a particular bacteria, virus or fungus even when the infection remains only in the respiratory or gastrointestinal tract.
Feedback from an early-access program for Synthetic Genomics' personal DNA workstation has started to emerge. And the initial news is positive, with a researcher at the University of California, San Francisco, reporting that the device is cutting the time and money it takes to synthesize DNA.
Researchers at the University of Maryland at Baltimore succeeded in delivering nanoparticles into cancer cells that changed packaged DNA into circular DNA, a breakthrough that may have applications for oncology and gene-based therapy.
Drug delivery specialist Genisphere announced that it has raised $2 million in private funding to advance its 3DNA nanotechnology platform through collaborations with pharma companies. The funders are existing investors including Corporate Fuel Partners.
While test strips and expensive polymerase chain reaction (PCR) machines exist in the Ebola detection market, scientists are after a medical device that can detect and prevent the spread of Ebola at a low cost.
Johns Hopkins researchers published a study showing they can use biodegradable nanoparticles to carry DNA to brain cancer cells. The animal study suggests that these vehicles could deliver what they call "death genes" to the cells, treating the cancer while preserving healthy brain cells in the process.